Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more
Summit Therapeutics PLC (SMMT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.484x
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.484x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-93.08 Million) by net assets ($192.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Summit Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YAMAGUCHI FINL GRP INC.
F:5FW
|
N/A |
|
Western Metal Materials Co Ltd
SHE:002149
|
0.000x |
|
Hubei Energy Group Co Ltd
SHE:000883
|
0.057x |
|
Xiamen C&D Inc
SHG:600153
|
-0.052x |
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
0.009x |
|
Bachem Holding AG
PINK:BCHMF
|
0.063x |
|
Hengan International Group Company Limited
F:HGNC
|
0.067x |
|
ASYMCHEM LAB.(TIAN.)H YC1
F:7K90
|
N/A |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2024)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $388.75 Million | $-142.11 Million | -0.366x | +63.00% |
| 2023-12-31 | $77.69 Million | $-76.76 Million | -0.988x | -200.93% |
| 2022-12-31 | $126.65 Million | $-41.58 Million | -0.328x | +62.33% |
| 2021-12-31 | $83.28 Million | $-72.59 Million | -0.872x | -43.93% |
| 2020-12-31 | $79.45 Million | $-48.11 Million | -0.606x | -137.76% |
| 2019-12-31 | $61.12 Million | $-15.56 Million | -0.255x | +59.56% |
| 2018-12-31 | $55.80 Million | $-35.14 Million | -0.630x | +57.66% |
| 2017-12-31 | $13.98 Million | $-20.79 Million | -1.487x | +57.20% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | -7.44% |
| 2014-12-31 | $22.55 Million | $-17.06 Million | -0.757x | +38.60% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -10.96% |
| 2011-12-31 | $3.78 Million | $-3.81 Million | -1.007x | -35.34% |
| 2010-12-31 | $5.82 Million | $-4.33 Million | -0.744x | -272.12% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.45% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.74% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -37.19% |
| 2005-12-31 | $23.38 Million | $-2.53 Million | -0.108x | -724.67% |
| 2004-12-31 | $26.53 Million | $-348.33K | -0.013x | -2.42% |
| 2003-12-31 | $142.31K | $-1.82K | -0.013x | -- |